MTVA Key Statistics, Chart & Performance
The current stock price of MTVA is 0.7134 USD. In the past month the price decreased by -26.84%.
MTVA Latest News, Press Relases and Analysis
MTVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About MTVA
Company Profile
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Company Info
METAVIA INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS US
Employees: 9
Phone: 18577029600
METAVIA INC / MTVA FAQ
What does MTVA do?
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Can you provide the latest stock price for METAVIA INC?
The current stock price of MTVA is 0.7134 USD. The price decreased by -4.78% in the last trading session.
Does METAVIA INC pay dividends?
MTVA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MTVA stock?
MTVA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for METAVIA INC?
METAVIA INC (MTVA) currently has 9 employees.
What is METAVIA INC worth?
METAVIA INC (MTVA) has a market capitalization of 17.27M USD. This makes MTVA a Nano Cap stock.
MTVA Technical Analysis
MTVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTVA. MTVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MTVA Financial Highlights
Over the last trailing twelve months MTVA reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS increased by 78.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.17% | ||
| ROE | -192.13% | ||
| Debt/Equity | 0 |
MTVA Forecast & Estimates
9 analysts have analysed MTVA and the average price target is 14.54 USD. This implies a price increase of 1937.43% is expected in the next year compared to the current price of 0.7134.